1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Vital Signs - Healthcare News - The Analyst's Perspect March 2014 Issue

Vital Signs - Healthcare News - The Analyst's Perspect March 2014 Issue

  • March 2014
  • -
  • Frost & Sullivan
  • -
  • 5 pages

Summary

Table of Contents

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gilead's Sovaldi, Sony's genomic partnership with Illumina, and Craig Venter’s latest venture, Human Longevity, Inc.


LIFE SCIENCES


A panel of experts convened in San Francisco, Calif., to discuss the cost-effectiveness of Sovaldi, Gilead’s breakthrough therapy for the chronic hepatitis C infection (CHC). Sovaldi has been priced at $1,000 per pill, translating to a total cost of $84,000 for a 12-week treatment course. Some patients with a tougher-to-treat viral strain will need a 24-week course, with a price tag of $168,000. The expert panel concluded that, although this new drug is an important breakthrough in the treatment of CHC, the benefit does not outweigh the cost for all patients, nor would the healthcare system be able to support coverage for all CHC patients. Thus, many managed care organizations may need to restrict this drug to only the sickest patients who have tried and failed cheaper standard therapies.


The Analyst’s Perspective by Debbie Toscano, Senior Industry Analyst, Life Sciences

Development of better antiviral drugs to fight CHC is one of the most competitive areas in the pharmaceutical industry. The need for better treatments is high due to the growing number of infected people developing liver damage as the population ages, modest cure rate of available treatments, and no preventative vaccine for this highly transmissible virus. Since most people infected with hepatitis C virus (HCV) are not aware that they are infected or even at risk of infection, the US Preventive Services Task Force has recently recommended that all people born between 1945 and 1956 receive a one-time screening, an action with the potential to increase the treatable population even more.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Respiratory Treatment Market in the US

  • April 2017
    8 pages
  • Respiratory Tre...  

  • United States  

View report >

Antipsychotic Market in the Netherlands

  • April 2017
    9 pages
  • Antipsychotic  

  • Netherlands  

View report >

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Related Market Segments :

Therapy
Hepatitis

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.